Cardiol Therapeutics has achieved its original enrollment target of 110 patients early in its Phase III MAVERIC trial for CardiolRx™, a drug aimed at reducing recurrent pericarditis risk. Due to fewer-than-expected recurrences observed in a blinded review, the company plans to expand enrollment to 150 patients to ensure robust data. Topline results are now expected by mid-2027, with existing capital sufficient to fund the trial through Q1 2028. This expansion aims to provide a stronger assessment of CardiolRx™'s effectiveness in preventing pericarditis recurrence.
Cardiol Therapeutics' Phase III MAVERIC trial update provides context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Sep 23, 2026 17:01 WIB: Of 100 priced US health-sector stocks, 47 rose and 42 fell today. Notable movers include BNGO at USD 1.78 with a 2.20% decline and a typical hold time of 49 days, RVTY at USD 140.62 down 1.88% with a 12-day hold, and HUM at USD 378.73 up 1.83% with an 81% sell order activity and a 53-day hold time.
A Snap insider has sold 20,000 shares as the company's stock has declined by 27% over the last year. This insider sale may signal concerns about the stock's near-term prospects or a personal decision to liquidate holdings. Investors should watch for ...
Analyst Daniel Sparks projects Sandisk's stock price to rise from about $1,790 to the low $2,000s by 2030. This growth forecast suggests the stock will not outperform the broader market during this period. Investors should consider this moderate outl...
Bitcoin briefly surged above $87,000 twice within 48 hours, peaking at $87,251 before settling around $86,400, maintaining a market cap near $1.74 trillion. This price action follows a 35% gain since mid-August, supported by strong technical indicato...
Bitcoin has achieved three consecutive months of price gains for the first time since 2012, rising about 4.8% in July, 25.2% in August, and roughly 10.9% in September 2026. This rare streak draws attention because a similar pattern in 2012 preceded a...
In September 2026, five monthly dividend stocks popular among Boomer investors demonstrated reliable income streams and growth. Realty Income, Agree Realty, STAG Industrial, Main Street Capital, and Gladstone Investment each either raised or maintain...
